A Challenging Diagnosis of Cushing’s Syndrome in Primary Care: A Case Report

Posted on May 11, 2026 by MaryO

Abstract

Cushing’s syndrome is a rare endocrine disorder characterized by an insidious course and multisystem manifestations, often leading to delayed diagnosis due to its nonspecific presentation. A 52-year-old woman with a history of type 2 diabetes mellitus and hypertension was followed in primary care for persistent musculoskeletal pain and worsening metabolic control, initially attributed to poor treatment adherence. Her condition progressively led to significant functional impairment, requiring the use of crutches for ambulation and ultimately resulting in medical retirement due to disability. After presenting with abdominal pain, a computed tomography scan incidentally revealed a 35 mm left adrenal mass suggestive of an adenoma. In light of the clinical context, further evaluation confirmed adrenocorticotropic hormone (ACTH)-independent hypercortisolism. The patient underwent left adrenalectomy and remains under clinical follow-up, with progressive improvement in metabolic parameters and functional status. This case highlights the importance of reassessing persistent symptoms and appropriately evaluating incidental findings in primary care, as well as the potential for significant functional decline in undiagnosed cases. Early recognition of atypical presentations may facilitate the diagnosis of rare endocrine disorders.

Introduction

Cushing’s syndrome is a rare endocrine disorder caused by prolonged exposure to excessive cortisol levels. Its clinical presentation is often insidious and characterized by multisystem involvement, including arterial hypertension, diabetes mellitus, cutaneous changes, osteoporosis, and muscle weakness. These manifestations are frequently nonspecific, contributing to delayed diagnosis and underrecognition by healthcare professionals [1,2].

In primary care, a patient-centered approach combined with longitudinal follow-up allows the identification of progressive and persistent changes, as well as the functional impact of symptoms. This case illustrates the role of the family physician in reassessing persistent complaints and integrating incidental findings, ultimately leading to the diagnosis of adrenocorticotropic hormone (ACTH)-independent hypercortisolism of adrenal origin.

Case Presentation

A 52-year-old female factory worker with a history of type 2 diabetes mellitus and arterial hypertension was regularly followed in a primary care setting. She repeatedly reported generalized musculoskeletal pain and progressive functional decline over several years.

Despite evaluation by multiple hospital specialties and prolonged physiotherapy, she maintained significant pain complaints with increasing limitation of daily activities. Glycated hemoglobin (HbA1c) was 8.6%, later 7.8% (reference: 4.0-5.6%) after therapeutic adjustment. Blood pressure was 170/90 mmHg, subsequently 153/100 mmHg. Lipid profile showed total cholesterol 264 mg/dL (reference: <200 mg/dL), low-density lipoprotein (LDL) cholesterol 175 mg/dL (reference: <130 mg/dL), and triglycerides 212 mg/dL (reference: <150 mg/dL). Despite treatment intensification, these parameters remained above target.

In parallel, her functional status progressively worsened, requiring assistance for ambulation or the use of crutches. This decline ultimately led to medical retirement due to disability.

Approximately three years after symptom onset, she presented to a private hospital emergency department with a six-month history of painful swelling in the left hypochondrium. Abdominal computed tomography revealed a 35 mm solid nodular lesion in the left adrenal gland, suggestive of an adenoma (Figure 1).

Abdominal-computed-tomography-scan-showing-left-adrenal-mass
Figure 1: Abdominal computed tomography scan showing left adrenal mass

Axial abdominal CT image demonstrating a 35 mm solid nodular lesion in the left adrenal gland (arrow), consistent with an adrenal adenoma.

At a subsequent primary care consultation, she presented with moon facies, facial plethora, proximal muscle atrophy, and scattered ecchymoses. Bone densitometry revealed severe osteoporosis (lumbar spine T-score −4.2, femoral T-score −2.6) (Figure 2) [3,4].

Bone-densitometry-showing-severe-osteoporosis
Figure 2: Bone densitometry showing severe osteoporosis

(A) Lumbar spine dual-energy X-ray absorptiometry (DEXA) scan demonstrating severe osteoporosis (T-score −4.2).
(B) Femoral DEXA scan showing reduced bone mineral density (T-score −2.6).

Laboratory studies showed elevated serum cortisol (727 nmol/L; reference: 171-536 nmol/L) with suppressed morning ACTH (1.5 ng/L; reference: 7.2-63.3 ng/L). Based on these findings, she was referred to endocrinology. In the endocrinology department, a 1 mg overnight dexamethasone suppression test showed cortisol of 637.24 nmol/L (reference: 171-536 nmol/L), confirming ACTH-independent hypercortisolism [1,2].

She subsequently underwent laparoscopic transperitoneal left adrenalectomy without complications. Histopathological examination confirmed an adrenocortical adenoma, showing a well-circumscribed lesion with diffuse architecture and cortical atrophy of the surrounding parenchyma. No evidence of necrosis, vascular invasion, or capsular invasion was identified. Immunohistochemical analysis demonstrated CYP11B1 positivity and CYP11B2 negativity, consistent with a cortisol-producing adenoma.

Following surgery, the patient remained under follow-up, with progressive improvement in metabolic parameters and functional status.

A timeline summarizing the clinical course, investigations, and management is presented in Figure 3.

Timeline-of-clinical-events,-investigations-and-management.
Figure 3: Timeline of clinical events, investigations and management.

ACTH: adrenocorticotropic hormone. Created by the authors using Canva (Sydney, Australia).

Discussion

Cushing’s syndrome is a rare condition, with an estimated incidence of two to three cases per million people per year [1]. Its clinical presentation is variable and often masked by common comorbidities such as diabetes mellitus and hypertension, which may delay diagnosis [2]. This overlap frequently contributes to diagnostic delay, often extending over several years [1,2].

Adrenal incidentalomas are increasingly identified due to widespread use of imaging, and their evaluation requires careful hormonal assessment to exclude functional lesions [5]. In this case, the incidental finding of an adrenal mass, combined with clinical suspicion, prompted further investigation and ultimately led to diagnosis. The progressive and multisystem nature of hypercortisolism often results in significant morbidity, including severe osteoporosis and functional decline, as observed in this patient [3]. Chronic exposure to excess cortisol is known to negatively impact bone metabolism and increase fracture risk [3].

The 1 mg overnight dexamethasone suppression test is widely used as an initial screening tool, with a cortisol cut-off of <1.8 μg/dL providing high sensitivity for the diagnosis of Cushing’s syndrome [1,2].

The holistic and continuous approach of the family physician allows recognition of subtle clinical changes and the functional impact of symptoms. This role is particularly relevant in slowly progressive and multisystem diseases such as Cushing’s syndrome.

It is important to note that patients with frequent consultations and persistent complaints may have their concerns undervalued. The tendency to attribute such presentations to anxiety, low pain tolerance, or poor adherence is understandable in a high-demand clinical setting but may contribute to delayed diagnosis of serious conditions.

Conclusions

This case highlights the importance of the family physician in recognizing and valuing persistent symptoms and their functional impact. The longitudinal follow-up was essential in raising suspicion and guiding diagnosis. In patients with repeated complaints, careful clinical assessment is crucial to avoid underestimation of potentially serious conditions. Particular attention should be given to unexplained functional decline, even when symptoms appear nonspecific. Maintaining clinical vigilance is fundamental to improving patient outcomes.

References

  1. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM: The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008, 93:1526-40. 10.1210/jc.2008-0125
  2. Fleseriu M, Auchus R, Bancos I, et al.: Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021, 9:847-75. 10.1016/S2213-8587(21)00235-7
  3. Kanis JA, Cooper C, Rizzoli R, Reginster JY: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019, 30:3-44. 10.1007/s00198-018-4704-5
  4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. (1994). https://iris.who.int/handle/10665/39142.
  5. Young WF Jr, Kebebew E: Evaluation and management of the adrenal incidentaloma. UpToDate. Connor RF (ed): Wolters Kluwer, Waltham; 2026.

From https://www.cureus.com/articles/480975-a-challenging-diagnosis-of-cushings-syndrome-in-primary-care-a-case-report#!/

Filed under: adrenal, Cushing's, symptoms | Tagged: , , , , | Leave a comment »

New discoveries offer possible Cushing’s disease cure

Posted on April 27, 2026 by MaryO

LOS ANGELES — More than a century has passed since the neurosurgeon and pathologist Harvey Cushing first discovered the disease that would eventually bear his name, but only recently have several key discoveries offered patients with the condition real hope for a cure, according to a speaker here.

There are several challenges clinicians confront in the diagnosis and treatment of Cushing’s disease, Shlomo Melmed, MB, ChB, FRCP, MACP, dean, executive vice president and professor of medicine at Cedars-Sinai Medical Center in Los Angeles, said during a plenary presentation. Patients who present with Cushing’s disease typically have depression, impaired mental function and hypertension and are at high risk for stroke, myocardial infarction, thrombosis, dyslipidemia and other metabolic disorders, Melmed said. Available therapies, which range from surgery and radiation to the somatostatin analogue pasireotide (Signifor LAR, Novartis), are often followed by disease recurrence. Cushing’s disease is fatal without treatment; the median survival if uncontrolled is about 4.5 years, Melmed said.

“This truly is a metabolic, malignant disorder,” Melmed said. “The life expectancy today in patients who are not controlled is apparently no different from 1930.”

The outlook for Cushing’s disease is now beginning to change, Melmed said. New targets are emerging for treatment, and newly discovered molecules show promise in reducing the secretion of adrenocorticotropic hormone (ACTH) and pituitary tumor size.

“Now, we are seeing the glimmers of opportunity and optimism, that we can identify specific tumor drivers — SST5, [epidermal growth factor] receptor, cyclin inhibitors — and we can start thinking about personalized, precision treatment for these patients with a higher degree of efficacy and optimism than we could have even a year or 2 ago,” Melmed said. “This will be an opportunity for us to broaden the horizons of our investigations into this debilitating disorder.”

Challenges in diagnosis, treatment

Overall, about 10% of the U.S. population harbors a pituitary adenoma, the most common type of pituitary disorder, although the average size is only about 6 mm and 40% of them are not visible, Melmed said. In patients with Cushing’s disease, surgery is effective in only about 60% to 70% of patients for initial remission, and overall, there is about a 60% chance of recurrence depending on the surgery center, Melmed said. Radiation typically leads to hypopituitarism, whereas surgical or biochemical adrenalectomy is associated with adverse effects and morbidity. Additionally, the clinical features of hypercortisolemia overlap with many common illnesses, such as obesity, hypertension and type 2 diabetes.

“There are thousands of those patients for every patient with Cushing’s disease who we will encounter,” Melmed said.

The challenge for the treating clinician, Melmed said, is to normalize cortisol and ACTH with minimal morbidity, to resect the tumor mass or control tumor growth, preserve pituitary function, improve quality of life and achieve long-term control without recurrence.

“This is a difficult challenge to meet for all of us,” Melmed said.

Available options

Pituitary surgery is typically the first-line option offered to patients with Cushing’s disease, Melmed said, and there are several advantages, including rapid initial remission, a one-time cost and potentially curing the disease. However, there are several disadvantages with surgery; patients undergoing surgery are at risk for postoperative venous thromboembolism, persistent hypersecretion of ACTH, adenoma persistence or recurrence, and surgical complications.

Second-line options are repeat surgery, radiation, adrenalectomy or medical therapy, each with its own sets of pros and cons, Melmed said.

“The reality of Cushing’s disease — these patients undergo first surgery and then recur, second surgery and then recur, then maybe radiation and then recur, and then they develop a chronic illness, and this chronic illness is what leads to their demise,” Melmed said. “Medical therapy is appropriate at every step of the spectrum.”

Zebrafish clues

Searching for new options, Melmed and colleagues introduced a pituitary tumor transforming gene discovered in his lab into zebrafish, which caused the fish to develop the hallmark features of Cushing’s disease: high cortisol levels, diabetes and cardiovascular disease. In the fish models, researchers observed that cyclin E activity, which drives the production of ACTH, was high.

Melmed and colleagues then screened zebrafish larvae in a search for cyclin E inhibitors to derive a therapeutic molecule and discovered R-roscovitine, shown to repress the expression of proopiomelanocortin (POMC), the pituitary precursor of ACTH.

In fish, mouse and in vitro human cell models, treatment with R-roscovitine was associated with suppressed corticotroph tumor signaling and blocked ACTH production, Melmed said.

“Furthermore, we asked whether or not roscovitine would actually block transcription of the POMC gene,” Melmed said. “It does. We had this molecule (that) suppressed cyclin E and also blocks transcription of POMC leading to blocked production of ACTH.”

In a small, open-label, proof-of-principal study, four patients with Cushing’s disease who received roscovitine for 4 weeks developed normalized urinary free cortisol, Melmed said.

Currently, the FDA Office of Orphan Products Development is funding a multicenter, phase 2, open-label clinical trial that will evaluate the safety and efficacy of two of three potential doses of oral roscovitine (seliciclib) in patients with newly diagnosed, persistent or recurrent Cushing disease. Up to 29 participants will be treated with up to 800 mg per day of oral seliciclib for 4 days each week for 4 weeks and enrolled in sequential cohorts based on efficacy outcomes.

“Given the rarity of the disorder, it will probably take us 2 to 3 years to recruit patients to give us a robust answer,” Melmed said. “This zebrafish model was published in 2011, and we are now in 2019. It has taken us 8 years from publication of the data to, today, going into humans with Cushing’s. Hopefully, this will light the pathway for a phase 2 trial.”

‘ Offering optimism’

Practitioners face a unique paradigm when treating patients with Cushing’s disease, Melmed said. Available first- and second-line therapy options often are not a cure for many patients, who develop multimorbidity and report a low quality of life.

“Then, we are kept in this difficult cycle of what to do next and, eventually, running out of options,” Melmed said. “Now, we can look at novel, targeted molecules and add those to our armamentarium and at least offer our patients the opportunity to participate in trials, or at least offer the optimism that, over the coming years, there will be a light at the end of the tunnel for their disorder.”

Melmed compared the work to Lucas Cranach’s Fons Juventutis (The Fountain of Youth). The painting, completed in 1446, shows sick people brought by horse-drawn ambulance to a pool of water, only to emerge happy and healthy.

“He was imagining this ‘elixir of youth’ (that) we could offer patients who are very ill and, in fact, that is what we as endocrinologists do,” Melmed said. “We offer our patients these elixirs. These Cushing’s patients are extremely ill. We are trying with all of our molecular work and our understanding of pathogenesis and signaling to create this pool of water for them, where they can emerge with at least an improved quality of life and, hopefully, a normalized mortality. That is our challenge.” – by Regina Schaffer

Reference:

Melmed S. From zebrafish to humans: translating discoveries for the treatment of Cushing’s disease. Presented at: AACE Annual Scientific and Clinical Congress; April 24-28, 2019; Los Angeles.

Disclosure: Melmed reports no relevant financial disclosures.

 

From https://www.healio.com/endocrinology/neuroendocrinology/news/online/%7B585002ad-640f-49e5-8d62-d1853154d7e2%7D/new-discoveries-offer-possible-cushings-disease-cure

Filed under: Cushing's, Meetings and Conferences, pituitary, symptoms, Treatments | Tagged: , , , , , , , , , , , , | Leave a comment »

Blood Lipid Levels Linked to High Blood Pressure in Cushing’s Disease Patients

Posted on April 25, 2026 by MaryO

High lipid levels in the blood may lead to elevated blood pressure in patients with Cushing’s disease, a Chinese study shows.

The study, “Evaluation of Lipid Profile and Its Relationship with Blood Pressure in Patients with Cushing’s Disease,” appeared in the journal Endocrine Connections.

Patients with Cushing’s disease often have chronic hypertension, or high blood pressure, a condition that puts them at risk for cardiovascular disease. While the mechanisms of Cushing’s-related high blood pressure are not fully understood, researchers believe that high levels of cortisol lead to chronic hypertension through increased cardiac output, vascular resistance, and reactivity to blood vessel constrictors.

In children and adults with Cushing’s syndrome, the relationship between increased cortisol levels and higher blood pressure has also been reported. Patients with Cushing’s syndrome may remain hypertensive even after surgery to lower their cortisol levels, suggesting their hypertension is caused by changes in blood vessels.

Studies have shown that Cushing’s patients have certain changes, such as increased wall thickness, in small arteries. The renin-angiotensin system, which can be activated by glucocorticoids like cortisol, is a possible factor contributing to vascular changes by increasing the uptake of LDL-cholesterol (LDL-C) — the “bad” cholesterol — in vascular cells.

Prior research showed that lowering cholesterol levels could benefit patients with hypertension and normal lipid levels by decreasing the stiffness of large arteries. However, the link between blood lipids and hypertension in Cushing’s disease patients is largely unexplored.

The study included 84 patients (70 women) referred to a hospital in China for evaluation and diagnosis of Cushing’s disease. For each patient, researchers measured body mass index, blood pressure, lipid profile, and several other biomarkers of disease.

Patients with high LDL-cholesterol had higher body mass index, blood pressure, cholesterol, triglycerides, and apolipoproteinB (apoB), a potential indicator of atherosclerosis and cardiovascular disease.

Data further revealed an association between blood pressure and lipid profile, including cholesterol, triglycerides, apoB and LDL-c. “The results strongly suggested that CHO (cholesterol), LDL-c and apoB might predict hypertension more precisely in [Cushing’s disease],” the scientists wrote.

They further add that high cholesterol, LDL-cholesterol, and apoB might be contributing to high blood pressure by increasing vessel stiffness.

Additional analysis showed that patients with higher levels of “bad” cholesterol — 3.37 mmol/L or higher — had higher blood pressure. This finding remained true, even when patients were receiving statins to lower their cholesterol levels.

No association was found between blood pressure and plasma cortisol, UFC, adrenocorticotropic hormone, or glucose levels in Cushing’s disease patients.

These findings raise some questions on whether lipid-lowering treatment for high blood pressure and cardiovascular disease would be beneficial for Cushing’s disease patients. Further studies addressing this question are warranted.

Adapted from https://cushingsdiseasenews.com/2018/04/24/blood-pressure-linked-lipid-levels-cushings-disease-study/

Filed under: adrenal, Clinical trials, Cushing's, pituitary, symptoms | Tagged: , , , , , , , , | Leave a comment »

Reasons You Have Flab Around Your Abdomen

Posted on April 24, 2026 by MaryO

Some diseases and conditions could be responsible for your abdominal fat.
Mita Majumdar | Updated: April 24, 2017 6:15 pm

Visceral fat or unhealthy belly fat that surrounds the liver and other organs in the abdomen puts you at risk for serious health problems, such as, metabolic syndrome, heart disease, and type 2 diabetes. But, what causes your pot belly or beer fat in the first place? The most obvious answers you will get is – ‘You are not exercising enough’, or, ‘you are eating too much of fatty foods or sugary foods’, or ‘you are not eating the right foods’, or ultimately, ‘It’s genetics! You got it from your parents’. All of these reasons are true, of course. However, some diseases/ disorders and conditions, too, could be responsible for your abdominal fat and these have nothing to do with not exercising or not eating right. Following are some of these disorders.

Cushing’s Syndrome

Cushing’s syndrome, also called hypercortisolism, is an endocrine disorder that occurs when your body is exposed to high cortisol levels over a long period of time. It is a treatable disorder, however, if it is chronic, the symptoms can last lifelong.

Symptoms: Symptoms vary according to the severity of the disorder. The characteristic symptoms include –

  • Fatty tissue deposits in the midsection
  • Fatty deposits in the upper back, especially between the shoulders, so that it resembles a hump
  • Puffy face
  • Violaceous stretch marks (pink or purple) on the arms, breast, stomach, and thighs that are more than 1 cm wide. [1]
  • Easy bruising
  • Fatigue
  • Hirsutism and irregularity in menstruation in women
  • Loss of libido and erectile dysfunction in men
  • Cognitive dysfunction, depression, unpredictable emotional outbursts, irritability is present in 70-85 percent of people with Cushing’s syndrome.[1]

Causes:

  • Overuse of corticosteroids
  • Overproduction of cortisol by the adrenal glands

Management:

  • Surgery is the first line of treatment for Cushing’s syndrome.
  • Medication include: [2]

a.Pituitary gland directed therapy

b.Adrenal-blocking drugs

c.Glucocorticoid receptor-antagonizing drugs

  • Pituitary radiotherapy

Addison’s disease

Addison’s disease, also called adrenal insufficiency, is a disorder where your adrenal glands produce insufficient hormones, especially, glucocorticoids including cortisol and aldosterone. It is a life-threatening disease that can affect anyone irrespective of their gender or age.

How do glucocorticoids influence abdominal fats? Glucocorticoids including cortisol convert the fats into energy in the liver. They also help your body respond to stress. When sufficient amount of glucocorticoids are not produced by the adrenal glands, the fats accumulate in the abdominal area, and you see it as flab around your middle.

Symptoms:

  • Hyperpigmentation
  • Extreme fatigue
  • Low blood sugar and low blood pressure
  • Salt craving as one of the functions of adrenal glands is to maintain the sodium-potassium balance in the body
  • Nausea, vomiting, abdominal pain
  • Weight loss but gain in abdominal fat

Causes:

  • Insufficient production of adrenal cortex hormones
  • Stopping of prescribed corticosteroids
  • Tuberculosis and other infections of adrenal glands
  • Spread of cancer to the adrenal glands

Management:

  • Oral corticosteroids or corticosteroid injections
  • Intravenous injections of hydrocortisone, saline solution, and dextrose in case of Addisonian crisis

Stress

Chronic stress is a very big cause of belly fat. When you are exposed to stress, a chain reaction starts in the body because of the dysregulation of HPA axis of the neuroendocrine system. HPA axis is a complex interaction between the hypothalamus, pituitary gland, and adrenal glands. The hypothalamus produces a corticotropin releasing hormone (CRH) and vasopressin. These together stimulate the secretion of adrenocorticotropic hormone (ACTH). ACTH is transported by the blood to the adrenal glands, which then produces corticosteroids, mainly, cortisol from cholesterol. One of the functions of cortisol is to signal the body to store fat, and specifically, the fat storage occurs in the abdominal area, where the cortisol receptors are greater. Researchers have found that stress causes hyperactivation of HPA axis, leading to accumulation of fat tissue, especially in the abdomen region.

So, the more and longer you are stressed (or if you are chronically stressed), chances are that you will be carrying more belly fat!

Ascites

Ascites is the buildup of fluid in the abdominal space. Ascites usually occurs in people with cancer, and it is then called malignant ascites. Onset of ascites is generally the terminal phase in cancer. Ascites also occurs in patients with liver cirrhosis, kidney failure, or heart disease.

Symptoms:

The first sign of ascites is an increase in abdominal girth accompanied by weight gain. [4] Although it looks like it is belly fat, it is actually the fluid that causes the bulging.

Other symptoms include:

  • Shortness of breath
  • Nausea and vomiting
  • Swelling in the feet and ankle
  • Decreased appetite, sense of fullness, bloating
  • Fatigue
  • Haemorrhoids

Management:

If the ascites is not causing any discomfort, it may not require any treatment. Treatment of ascites can have many side effects. Talk to your doctor before you go in for management/ treatment.

Abdominal hernia

Abdominal hernia is a swelling or a bulge in the abdominal area where an organ or fatty tissue pushes through a weak spot in the abdominal wall. The abdominal wall is made up of tough connective tissue and tendons that stretch from the ribs to the groin. Depending on the position of the weakness in your abdominal wall, the hernia can be inguinal (groin), femoral (upper thigh), umbilical (belly button), hiatal (upper stomach), or even incisional. Incisional hernia can occur when the intestine pushes through a weak spot at the site of abdominal surgery.

Symptoms:

  • Visible bulge that may or may not cause discomfort
  • Feeling of heaviness in the abdomen
  • Sharp pain when you strain or lift objects

Causes:

  • Constipation and diarrhoea
  • Persistent coughing and sneezing
  • Straining or suddenly lifting a heavy object

Management:

  • Umbilical hernia, common in young children, mostly resolves by itself as the abdominal muscles get stronger.
  • Other abdominal hernia normally do not resolve by themselves. Doctors suggest waiting and watching.
  • If treatment is required, surgery is the only option. Surgery involves pushing the hernia back into the abdomen and repairing the abdominal wall.

Menopause

Menopause is certainly not a disease or a disorder. It is the time in a woman’s life when she stops menstruating and cannot become pregnant because her ovaries stop producing the required amounts of hormones oestrogen and progesterone. A woman reaches menopause when she has not had her periods for 12 months.

Symptoms:

  • Hot flashes and/ or night sweats
  • Vaginal dryness
  • Mood swings
  • Sleep disturbances

It is very common to gain belly fat during menopause. This is because of the low oestrogen levels. Oestrogen seems to influence the distribution of fat in the body, in a way that the fat is redistributed from the hips, buttocks, and thighs to the belly. However, a study published in the journal Metabolism reported that though women did significantly gain belly fat, especially deep inside the belly, relative fat distribution is not significantly different after menopause. [5] But the fact remains that women do gain flab in the abdomen after menopause.

Belly fat can be seriously harmful. If your belly fat is not because of the above-mentioned conditions, you can lose it by adopting a healthy lifestyle that includes sleeping enough, exercising regularly, eating right, and reducing stress.

Reference

  1. Sharma ST, Nieman LK, Feelders RA. Cushing’s syndrome: epidemiology and developments in disease management. Clinical Epidemiology. 2015;7:281-293. doi:10.2147/CLEP.S44336.
  1. Feelders RA, Hofland LJ. Medical treatment of Cushing’s disease. J Clin Endocrinol Metab. 2013;98:425–438.
  1. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann N Y Acad Sci. 2006 Nov;1083:77-110.
  1. Sinicrope FA. Ascites. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.
  2. Franklin RM, Ploutz-Snyder L, Kanaley JA. Longitudinal changes in abdominal fat distribution with menopause. Metabolism. 2009 Mar;58(3):311-5. doi: 10.1016/j.metabol.2008.09.030.

Adapted from http://www.thehealthsite.com/diseases-conditions/reasons-you-have-flab-around-your-abdomen-f0417/

 

Filed under: adrenal, Cushing's, Rare Diseases, symptoms | Tagged: , , , , , , , , , , | Leave a comment »

Day 22, Cushing’s Awareness Challenge

Posted on April 22, 2026 by MaryO

This is a tough one.  Sometimes I’m in “why me” mode.  Why Cushing’s?  Why cancer?  Unfortunately, there’s not a thing I can do about either.  Cushing’s, who knows the risk factors?  For kidney cancer I found out the risk factors and nearly none apply to me. So why? But why not?  No particular reason why I should be exempt from anything.

Since there’s nothing to be done with the exception of trying to do things that could harm my remaining kidney, I have to try to make the best of things.  This is my life.  It could be better but it could be way worse.

One of the Challenge topics was to write about “My Dream Day” so here’s mine…

I’d wake up on my own – no snooze alarms – at about 8 am, sun streaming through the window.  I’d we well rested and not have had any nightmares the night before.  I remember my son is home for a visit but I let him sleep in for a while.

I’d get out for a bike ride or a brisk walk, come home, head for the hot tub then shower.  I’d practice the piano for a bit, then go out to lunch with friends, taking Michael with me.  While we’re out, the maid will come in and clean the house.

After lunch, maybe a little technology shopping/buying.  Then the group of us go to one of our homes for piano duets, trios, 2-piano music.

When we get home, it’s immaculately clean and I find that the Prize Patrol has visited and left a substantial check.

I had wisely left something for dinner in the Ninja so dinner is ready.  After dinner, I check online and find no urgent email, no work that needs to be done, no bills that need to be paid, no blog challenge posts to write…

I wake up from My Dream Day and realize that this is so far from real life, so I re-read The Best Day of My Life  and am happy that I’m not dealing with anything worse.

Filed under: Cancer, Cushing's, symptoms, Thankfulness | Tagged: , , , , , , , , | Leave a comment »

Next Page »